Current Urology Reports

, 18:78 | Cite as

Convective Radiofrequency Water Vapor Thermal Therapy with Rezūm System

Benign Prostatic Hyperplasia (K McVary, Section Editor)
  • 156 Downloads
Part of the following topical collections:
  1. Topical Collection on Benign Prostatic Hyperplasia

Abstract

Purpose

Lower urinary tract symptoms (LUTS) secondary to benign prostatic hyperplasia (BPH) are amongst the most commonly treated conditions by urologists. Minimally invasive therapies for the treatment of BPH/LUTS have garnered increased interest as new technology has emerged, improving durability, efficacy, and safety. This paper reviews the most recent literature regarding water vapor therapy, a convective thermal therapy that ablates prostatic tissue.

Recent Findings

The current literature includes a pilot study of 65 men and a randomized controlled trial (RCT) of 197 men investigating the efficacy and safety profile of water vapor therapy up to 2 years. Subjects treated with water vapor therapy demonstrated a 51% reduction in IPSS from baseline, sustained at 24 months (p < 0.0001). Durable improvements in max flow rate (Qmax) and quality of life (QoL) were also achieved, while no changes in sexual function were observed. Reporting of adverse events (AEs) reveals predominantly Clavien grade I complications that were self-limited.

Summary

The clinical efficacy and safety of water vapor therapy are durable to 24 months making it an attractive alternative for patients seeking a minimally invasive treatment for LUTS due to BPH.

Keywords

Prostate Prostatic hyperplasia Lower urinary tract symptoms Thermal conductivity Minimally invasive therapies 

Notes

Compliance with Ethical Standards

Conflict of Interest

Sevann Helo and Bradley Holland each declare no potential conflicts of interest.

Kevin T. McVary reports and Lilly/ICOS Self 1/1/11 Present Consultant or Advisor, Scientific Study or Trial, Honorarium, Principal Investigator Y Tadalafil ED and BPHÐIDDK Self 1/1/11 Present Principal Investigator and consultant Y N/A OAB and EDÛoston Scientific (formerly AMS) Self 7/1/13 Present Principal Investigator—Fellowship Grant Y N/A ED and is a section editor for Current Urology Reports.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

References

Papers of particular interest, published recently, have been highlighted as: • Of importance

  1. 1.
    Logie J, Clifford GM, Farmer RD. Incidence, prevalence and management of lower urinary tract symptoms in men in the UK. BJU Int. 2005;95(4):557–62.CrossRefPubMedGoogle Scholar
  2. 2.
    Wei JT, Calhoun E, Jacobsen SJ. Urologic diseases in america project: benign prostatic hyperplasia. J Urol. 2008;179(5 Suppl):S75–80.CrossRefPubMedGoogle Scholar
  3. 3.
    Hutchison A, Farmer R, Chapple C, Berges R, Pientka L, Teillac P, et al. Characteristics of patients presenting with LUTS/BPH in six European countries. Eur Urol. 2006;50(3):555–61. discussion 62CrossRefPubMedGoogle Scholar
  4. 4.
    Parsons JK, Wilt TJ, Wang PY, Barrett-Connor E, Bauer DC, Marshall LM. Progression of lower urinary tract symptoms in older men: a community based study. J Urol. 2010;183(5):1915–20.CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    Roehrborn CG. Current medical therapies for men with lower urinary tract symptoms and benign prostatic hyperplasia: achievements and limitations. Rev Urol. 2008;10(1):14–25.PubMedPubMedCentralGoogle Scholar
  6. 6.
    Bhowmick P, Coad J, Bhowmick S, Pryor J, Larson T, De La Rosette J, et al. In vitro assessment of the efficacy of thermal therapy in human benign prostatic hyperplasia. Int J Hyperth. 2004;20(4):421–39.CrossRefGoogle Scholar
  7. 7.
    Hahn DW, Özişik MN. Heat Conduction Fundamentals. Heat Conduction, Third Edition. 2012:1–39.Google Scholar
  8. 8.
    • Dixon CM, Rijo Cedano E, Mynderse LA, Larson TR. Transurethral convective water vapor as a treatment for lower urinary tract symptomatology due to benign prostatic hyperplasia using the Rezum((R)) system: evaluation of acute ablative capabilities in the human prostate. Res Rep Urol. 2015;7:13–8. Histographic and radiographic of a patient after the Rezum procedure shows thermal ablation isolated to the transition zone. PubMedPubMedCentralGoogle Scholar
  9. 9.
    • Dixon C, Cedano ER, Pacik D, Vit V, Varga G, Wagrell L, et al. Efficacy and safety of Rezum system water vapor treatment for lower urinary tract symptoms secondary to benign prostatic hyperplasia. Urology. 2015;86(5):1042–7. Pilot study for the Rezum procedure showing improvements in IPSS and Qmax sustainable for 12 months with no sexual side effects. CrossRefPubMedGoogle Scholar
  10. 10.
    • Mynderse LA, Hanson D, Robb RA, Pacik D, Vit V, Varga G, et al. Rezum system water vapor treatment for lower urinary tract symptoms/benign prostatic hyperplasia: validation of convective thermal energy transfer and characterization with magnetic resonance imaging and 3-dimensional renderings. Urology. 2015;86(1):122–7. MRI shows 38% reduction in prostate transition zone volume. CrossRefPubMedGoogle Scholar
  11. 11.
    Fine SW, Reuter VE. Anatomy of the prostate revisited: implications for prostate biopsy and zonal origins of prostate cancer. Histopathology. 2012;60(1):142–52.CrossRefPubMedGoogle Scholar
  12. 12.
    McNeal JE. The zonal anatomy of the prostate. Prostate. 1981;2(1):35–49.CrossRefPubMedGoogle Scholar
  13. 13.
    Dixon C, Cedeno ER, Pacik D, Varga G, Vit V, Mynderse L. PD26-09 transurethral water vapor therapy for BPH; 1-year clinical results of the first-in-man and REZūM® I clinical trials using the REZūM® system. J Urol. 2014;191(4):e762.CrossRefGoogle Scholar
  14. 14.
    Roehrborn CG, Gange SN, Shore ND, Giddens JL, Bolton DM, Cowan BE, et al. The prostatic urethral lift for the treatment of lower urinary tract symptoms associated with prostate enlargement due to benign prostatic hyperplasia: the L.I.F.T. Study. J Urol. 2013;190(6):2161–7.CrossRefPubMedGoogle Scholar
  15. 15.
    Norby B, Nielsen HV, Frimodt-Moller PC. Transurethral interstitial laser coagulation of the prostate and transurethral microwave thermotherapy vs transurethral resection or incision of the prostate: results of a randomized, controlled study in patients with symptomatic benign prostatic hyperplasia. BJU Int. 2002;90(9):853–62.CrossRefPubMedGoogle Scholar
  16. 16.
    Bruskewitz R, Issa MM, Roehrborn CG, Naslund MJ, Perez-Marrero R, Shumaker BP, et al. A prospective, randomized 1-year clinical trial comparing transurethral needle ablation to transurethral resection of the prostate for the treatment of symptomatic benign prostatic hyperplasia. J Urol. 1998;159(5):1588–93. discussion 93-4CrossRefPubMedGoogle Scholar
  17. 17.
    Cimentepe E, Unsal A, Saglam R. Randomized clinical trial comparing transurethral needle ablation with transurethral resection of the prostate for the treatment of benign prostatic hyperplasia: results at 18 months. J Endourol. 2003;17(2):103–7.CrossRefPubMedGoogle Scholar
  18. 18.
    Mosli HA, Abdel-Meguid TA, Abdulwahhab MH, Al-Sayyad A, Farsi HM, Tayib A. Photoselective vaporization of the prostate using GreenLight 120-W lithium triborate laser to treat symptomatic benign prostatic hyperplasia: a single-centre prospective study. Can Urol Assoc J. 2013;7(3–4):E193–6.CrossRefPubMedPubMedCentralGoogle Scholar
  19. 19.
    Bachmann A, Tubaro A, Barber N, d'Ancona F, Muir G, Witzsch U, et al. 180-W XPS GreenLight laser vaporisation versus transurethral resection of the prostate for the treatment of benign prostatic obstruction: 6-month safety and efficacy results of a European multicentre randomised trial—the GOLIATH study. Eur Urol. 2014;65(5):931–42.CrossRefPubMedGoogle Scholar
  20. 20.
    • McVary KT, Gange SN, Gittelman MC, Goldberg KA, Patel K, Shore ND, et al. Minimally invasive prostate convective water vapor energy ablation: a multicenter, randomized, controlled study for the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia. J Urol. 2016;195(5):1529–38. Randomized control trial of the Rezum system showed 50% reduction in IPSS at 3, 6, and 12 months. Peak flow rate increased by 6.2 ml per second. No erectile dysfunction reported in this cohort. CrossRefPubMedGoogle Scholar
  21. 21.
    McVary K, Mynderse L, Gange S, Gittelman M, Goldberg K, Patel K, et al. Pii-lba1 using the thermal energy of convectively delivered water vapor for the treatment of lower urinary tract symptoms due to benign prostatic hyperplasia: the Rezum II study. J Urol. 2015;193(4):e495.CrossRefGoogle Scholar
  22. 22.
    • McVary KT, Gange SN, Gittelman MC, Goldberg KA, Patel K, Shore ND, et al. Erectile and ejaculatory function preserved with convective water vapor energy treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia: randomized controlled study. J Sex Med. 2016;13(6):924–33. Throrough evaluation of sexual health in men included in the randomized controlled trial of Rezum showed no treatment or device related de novo erectile dysfunction. CrossRefPubMedGoogle Scholar
  23. 23.
    Roehrborn CG, Gange SN, Gittelman MC, Goldberg KA, Patel K, Shore ND, et al. Convective radiofrequency water vapor thermal therapy with Rezum system: durable two-year results of randomized controlled and prospective crossover studies for treatment of lower urinary tract symptoms due to benign prostatic hyperplasia. J Urol. 2016;Google Scholar
  24. 24.
    McVary KT, Roehrborn CG, Avins AL, Barry MJ, Bruskewitz RC, Donnell RF, et al. Update on AUA guideline on the management of benign prostatic hyperplasia. J Urol. 2011;185(5):1793–803.CrossRefPubMedGoogle Scholar
  25. 25.
    Dixon CM, Cedano ER, Pacik D, Vit V, Varga G, Wagrell L, et al. Two-year results after convective radiofrequency water vapor thermal therapy of symptomatic benign prostatic hyperplasia. Res Rep Urol. 2016;8:207–16.PubMedPubMedCentralGoogle Scholar
  26. 26.
    Rosen RC, Wei JT, Althof SE, Seftel AD, Miner M, Perelman MA. Association of sexual dysfunction with lower urinary tract symptoms of BPH and BPH medical therapies: results from the BPH registry. Urology. 2009;73(3):562–6.CrossRefPubMedGoogle Scholar
  27. 27.
    Arai Y, Aoki Y, Okubo K, Maeda H, Terada N, Matsuta Y, et al. Impact of interventional therapy for benign prostatic hyperplasia on quality of life and sexual function: a prospective study. J Urol. 2000;164(4):1206–11.CrossRefPubMedGoogle Scholar
  28. 28.
    Gacci M, Eardley I, Giuliano F, Hatzichristou D, Kaplan SA, Maggi M, et al. Critical analysis of the relationship between sexual dysfunctions and lower urinary tract symptoms due to benign prostatic hyperplasia. Eur Urol. 2011;60(4):809–25.CrossRefPubMedGoogle Scholar
  29. 29.
    Hoffman RM, Monga M, Elliott SP, Macdonald R, Langsjoen J, Tacklind J, et al. Microwave thermotherapy for benign prostatic hyperplasia. The Cochrane database of systematic reviews. 2012(9):Cd004135.Google Scholar
  30. 30.
    Bouza C, Lopez T, Magro A, Navalpotro L, Amate JM. Systematic review and meta-analysis of transurethral needle ablation in symptomatic benign prostatic hyperplasia. BMC Urol. 2006;6:14.CrossRefPubMedPubMedCentralGoogle Scholar
  31. 31.
    Kursh ED, Concepcion R, Chan S, Hudson P, Ratner M, Eyre R. Interstitial laser coagulation versus transurethral prostate resection for treating benign prostatic obstruction: a randomized trial with 2-year follow-up. Urology. 2003;61(3):573–8.CrossRefPubMedGoogle Scholar
  32. 32.
    Rassweiler J, Teber D, Kuntz R, Hofmann R. Complications of transurethral resection of the prostate (TURP)—incidence, management, and prevention. Eur Urol. 2006;50(5):969–79. discussion 80CrossRefPubMedGoogle Scholar
  33. 33.
    Roehrborn C, McConnell J, Barry M, Benaim E, Bruskewitz R, Blute M, et al., editors. American Urological Association guideline: management of benign prostatic hyperplasia (BPH). American Urological Association; 2003.Google Scholar
  34. 34.
    Fitzpatrick JM, Desgrandchamps F, Adjali K, Gomez Guerra L, Hong SJ, El Khalid S, et al. Management of acute urinary retention: a worldwide survey of 6074 men with benign prostatic hyperplasia. BJU Int. 2012;109(1):88–95.CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2017

Authors and Affiliations

  • Sevann Helo
    • 1
  • Bradley Holland
    • 1
  • Kevin T. McVary
    • 1
  1. 1.Division of UrologySouthern Illinois University School of MedicineSpringfieldUSA

Personalised recommendations